Emergency departments face challenges in detecting suicidality among trauma patients, highlighting the need for effective screening and intervention strategies.
Vol 43, Issue 1
Psychiatric Times is excited to embrace change with new digital editions and engaging content, and invite you, our readers, to explore diverse topics across multiple platforms.
Psychiatric Times embraces innovation with interactive digital issues and a new print format, enhancing accessibility for psychiatric clinicians.
Psychiatric Times is adapting to the evolving media landscape, focusing on impactful stories and insights, starting with schizophrenia and lifestyle psychiatry.
Xanomeline/trospium emerges as a groundbreaking schizophrenia treatment, showcasing efficacy and safety while highlighting challenges in clinical adoption.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Accepts Investigational New Drug Application for COMP360 for PTSD
2
New Phase 3 Clinical Vocal Biomarker Data on Brilaroxazine to Treat Negative Symptoms in Schizophrenia
3
It’s Not Normal: A Discussion of Psychosis in Epilepsy
4
FDA Grants Breakthrough Therapy Designation to Alixorexton for the Treatment of Narcolepsy Type 1
5